A Study of a Single Dose of ASP3291 in Subjects With Mild to Moderately Active Ulcerative Colitis
| Status: | Archived |
|---|---|
| Conditions: | Colitis, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | August 2010 |
| End Date: | October 2011 |
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of ASP3291 Following a Single Oral Dose in Subjects With Mild to Moderately Active Ulcerative Colitis
The purpose of this study is to determine the pharmacokinetics (PK) and to assess safety and
tolerability of a single dose of ASP3291 in subjects with mild to moderately active
ulcerative colitis.
After an 11-day screening period, subjects check into a clinic, are dosed on Day 1 and stay
in the clinic for 4 days to monitor pharmacokinetic and safety parameters.
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials